摘要
随着对非酒精性脂肪性肝病(NAFLD)研究的进一步深入,新证据、新理念和新方法的不断出现,中华医学会肝病学分会以国内外脂肪性肝病最新研究进展为依据,在既往指南基础上进行了全面更新和修订,发布了《代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)》.本文介绍了新版指南在相关术语[代谢相关脂肪性肝病(MAFLD)]、临床分型分期、诊断标准以及自然史等方面的更新.新版指南尤其强化了进展性肝纤维化的筛查、评估、无创诊断在MAFLD疾病管理中的重要性,对MAFLD多学科团队协作管理也更为积极.随着新版指南的推行与应用,将进一步提升我国MAFLD患者的筛查、诊断、治疗和随访等方面的规范化,以改善广大患者的预后.
Abstract
With further in-depth studies on non-alcoholic fatty liver disease(NAFLD),new evidence,concepts,and methods continue to emerge.Chinese Society of Hepatology,Chinese Medical Association,comprehensively updated and revised the previous guidelines based on the latest research advances in fatty liver disease in China and globally and released Clinical practice guideline of prevention and treatment of metabolic dysfunction-associated(non-alcoholic)fatty liver disease(2024 edition).This article introduces the updates in the new edition of the guideline from the aspects of related terms(metabolic associated fatty liver disease[MAFLD]),clinical typing and staging,diagnostic criteria,and natural history.The guideline particularly emphasizes the importance of screening,assessment,and noninvasive diagnosis of progressive liver fibrosis in disease management and proposes active multidisciplinary collaboration in the management of MAFLD.With the implementation and application of the new edition of the guideline,the standardization of screening,diagnosis,treatment and follow-up of MAFLD patients in China will be further improved to improve the prognosis of the majority of patients.
维普
万方数据